Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 6;24(1):13.
doi: 10.1186/s12935-024-03209-4.

Clinical applications and perspectives of circulating tumor DNA in gastric cancer

Affiliations
Review

Clinical applications and perspectives of circulating tumor DNA in gastric cancer

Jing-Han Li et al. Cancer Cell Int. .

Abstract

Gastric cancer remains a leading cause of cancer-related death worldwide, largely due to inadequate screening methods, late diagnosis, and limited treatment options. Liquid biopsy has emerged as a promising non-invasive approach for cancer screening and prognosis by detecting circulating tumor components like circulating tumor DNA (ctDNA) in the blood. Numerous gastric cancer-specific ctDNA biomarkers have now been identified. CtDNA analysis provides insight into genetic and epigenetic alterations in tumors, holding promise for predicting treatment response and prognosis in gastric cancer patients. This review summarizes current research on ctDNA biology and detection technologies, while highlighting clinical applications of ctDNA for gastric cancer diagnosis, prognosis, and guiding treatment decisions. Current challenges and future perspectives for ctDNA analysis are also discussed.

Keywords: Biomarker; Circulating tumor DNA; Gastric cancer; Liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Clinical applications of liquid biopsy in gastric cancer. Liquid biopsy, including circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), extracellular vesicle, and circulating tumor cell (CTC), has gained popularity as a valuable tool in clinical applications of gastric cancer
Fig. 2
Fig. 2
Detection methods of ctDNA in gastric cancer. Quantitative and qualitative changes of ctDNA in plasma provide valuable information for cancer. Quantitative change refers to the total ctDNA level, while qualitative changes include ctDNA mutations and methylation changes
Fig. 3
Fig. 3
High-frequency genetic markers associated with gastric cancer and their involvement in key cellular pathways

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Adeniji N, Dhanasekaran R. Current and emerging tools for hepatocellular carcinoma surveillance. Hepatol Commun. 2021;5(12):1972–1986. doi: 10.1002/hep4.1823. - DOI - PMC - PubMed
    1. Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 2009;15(22):2689–2692. doi: 10.3748/wjg.15.2689. - DOI - PMC - PubMed
    1. Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, Yan C. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS ONE. 2015;10(11):e0142080. doi: 10.1371/journal.pone.0142080. - DOI - PMC - PubMed
    1. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33. doi: 10.1007/s10120-013-0259-5. - DOI - PubMed

LinkOut - more resources